Amgen Inc logo

Amgen Inc(AMGN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
5-STAR RATING
STRONG BUY
BUY for 20 days
PROFIT SINCE LAST BUY
+9.58% ▲
LAST CLOSE
$465.67
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for AMGN

11/13/2026: AMGN (5-star) is a STRONG-BUY. BUY for 20 days. Simulated Profits (9.58%). Updated daily EoD!

Amgen Inc is a major global biotechnology company specializing in innovative human therapeutics for oncology, cardiovascular disease, inflammation, and rare diseases. The company's key business strengths include robust biologics manufacturing expertise, high operating margins, and strong cash generation from leading products like Repatha and Tezspire. Its primary growth opportunity centers on expanding its rare disease portfolio and advancing promising late-stage pipeline assets such as obesity candidate MariTide. However, key risks include heavy debt from recent acquisitions and accelerating revenue erosion from biosimilar competition facing legacy blockbusters like Prolia. The stock suits dividend and value-oriented investors seeking stable cash flows, while requiring monitoring of patent cliffs and clinical trial progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitAmgen offers steady mid-single-digit revenue expansion and exciting pipeline catalysts, but lacks hyper-growth characteristics.
Momentum investorStrong fit while signal remains positiveMomentum fit depends on favorable near-term clinical readouts and positive technical price trends.
Value investorMixed fitReasonable valuation multiples are balanced by high debt levels and patent expiration risks.
Dividend investorStrong fitAmgen provides a solid dividend yield backed by resilient free cash flow and a history of payout growth.
Low-risk investorMediumWhile established and cash-generative, biopharmaceutical regulatory and pipeline execution risks introduce moderate volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumBiotech shares can fluctuate based on clinical trial outcomes, regulatory decisions, and broader market conditions.
Valuation riskMediumValuation depends heavily on successful pipeline delivery to offset legacy patent cliffs.
Competition riskHighIntense competition from major biopharma peers and biosimilar manufacturers threatens market share.
Business qualityStrongAmgen possesses a high-quality franchise with leading biologics manufacturing expertise and robust operating margins.
Dividend incomeLowDividend payouts are well-supported by robust and predictable free cash flow generation.
Execution riskMedium / highSuccessful integration of acquired assets and delivery of late-stage pipeline candidates are critical for long-term growth.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 251.89B USD
Price to earnings Ratio 27
1Y Target Price 431.81
Price to earnings Ratio 27
1Y Target Price 431.81
Volume (30-day avg) 2.7M shares
Beta 0.42
52 Weeks Range 306.13 - 483.99
Updated Date 11/15/2026
52 Weeks Range 306.13 - 483.99
Updated Date 11/15/2026
Dividends yield (FY) 2.13%
Basic EPS (TTM) 17.25

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - General

BUY participation
77.8%
Active BUY / eligible
7 / 9
30-Day BUY Count Change
+4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit 61.43%
Avg. Invested days 53
Today’s Advisory Strong Buy
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
AMGN receives a 4-star rating, supported by strong unit economics, solid company fundamentals, solid quantitative characteristics, and solid analyst coverage. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
AMGN has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+88.5%) and strong cash generation (FCF margin 22.0%) are partially offset by moderate revenue growth (+9.9%), very low insider ownership of 0.57%.

Financial Health Rating

★★★★★
AMGN's financial health is supported by strong cash strength, including free-cash-flow generation of $8.1B (22.0% of revenue). Liquidity is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is AMGN's strongest growth driver at +88.5% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+9.9%, moderate) and free-cash-flow growth (-22.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 84.9% and approximately 99.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.57%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 9.13%
Vanguard Capital Management, LLC 6.52%
State Street Corp 5.65%
Capital World Investors 5.38%
Amvescap Plc. 3.02%

Unit Economics (Per $1K Revenue)

★★★★★
AMGN generates approximately $708 of gross profit, $291 of operating income, and $220 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins and strong cash conversion support the rating, although capital efficiency remains solid.

Economic Dimensions

★★★★★
Effective Tax Rate: 14.09%

Quantitative Style Profile

★★★★★
AMGN has a high-quality, large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltLow VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
General Medicine & Bone HealthIncludes key products like Prolia, Xgeva, and Evenity targeting osteoporosis and bone density disorders.These products form a major revenue foundation, though they face near-term generic erosion.
Cardiovascular & InflammationIncludes blockbuster therapies such as Repatha for cholesterol and Otezla for psoriasis.Repatha acts as a powerful volume growth engine offsetting declines in older franchises.
Rare DiseasesSpecialized medicines acquired via Horizon Therapeutics, including Tepezza and Krystexxa.Adds high-margin, specialized revenue streams diversifying the core portfolio.
Oncology & BiosimilarsIncludes oncology products like Blincyto and Kyprolis, alongside a growing portfolio of biosimilar drugs.Provides balanced exposure to cancer treatments and cost-effective alternatives to expensive biologics.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-03
When After Market
Estimate 5.74
Actual 6.45

Profitability

Profit Margin 24.14%
Operating Margin (TTM) 34.12%

Management Effectiveness

Return on Assets (TTM) 8.91%
Return on Equity (TTM) 78.35%

Valuation

Trailing PE 27
Forward PE 19.05
Enterprise Value 292.70B
Price to Sales(TTM) 6.47
Enterprise Value 292.70B
Price to Sales(TTM) 6.47
Enterprise Value to Revenue 7.52
Enterprise Value to EBITDA 16.11
Shares Outstanding 540.91M
Shares Floating 539.44M
Shares Outstanding 540.91M
Shares Floating 539.44M
Percent Insiders 0.57
Percent Institutions 84.89

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.